Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 25;325(20):2067-2075.
doi: 10.1001/jama.2021.6118.

α2-Adrenergic Agonists or Stimulants for Preschool-Age Children With Attention-Deficit/Hyperactivity Disorder

Affiliations

α2-Adrenergic Agonists or Stimulants for Preschool-Age Children With Attention-Deficit/Hyperactivity Disorder

Elizabeth Harstad et al. JAMA. .

Erratum in

  • Error in Results.
    [No authors listed] [No authors listed] JAMA. 2021 Oct 12;326(14):1440. doi: 10.1001/jama.2021.16131. JAMA. 2021. PMID: 34636871 Free PMC article. No abstract available.
  • Corrected Classification of Drugs in Table.
    [No authors listed] [No authors listed] JAMA. 2024 Jul 16;332(3):257. doi: 10.1001/jama.2024.11398. JAMA. 2024. PMID: 38884984 Free PMC article. No abstract available.

Abstract

Importance: Attention-deficit/hyperactivity disorder (ADHD) is diagnosed in approximately 2.4% of preschool-age children. Stimulants are recommended as first-line medication treatment. However, up to 25% of preschool-age children with ADHD are treated with α2-adrenergic agonist medications, despite minimal evidence about their efficacy or adverse effects in this age range.

Objective: To determine the frequency of reported improvement in ADHD symptoms and adverse effects associated with α2-adrenergic agonists and stimulant medication for initial ADHD medication treatment in preschool-age children.

Design, setting, and participants: Retrospective electronic health record review. Data were obtained from health records of children seen at 7 outpatient developmental-behavioral pediatric practices in the Developmental Behavioral Pediatrics Research Network in the US. Data were abstracted for 497 consecutive children who were younger than 72 months when treatment with an α2-adrenergic agonist or stimulant medication was initiated by a developmental-behavioral pediatrician for ADHD and were treated between January 1, 2013, and July 1, 2017. Follow-up was complete on February 27, 2019.

Exposures: α2-Adrenergic agonist vs stimulant medication as initial ADHD medication treatment.

Main outcomes and measures: Reported improvement in ADHD symptoms and adverse effects.

Results: Data were abstracted from electronic health records of 497 preschool-age children with ADHD receiving α2-adrenergic agonists or stimulants. Median child age was 62 months at ADHD medication initiation, and 409 children (82%) were males. For initial ADHD medication treatment, α2-adrenergic agonists were prescribed to 175 children (35%; median length of α2-adrenergic agonist use, 136 days) and stimulants were prescribed to 322 children (65%; median length of stimulant use, 133 days). Improvement was reported in 66% (95% CI, 57.5%-73.9%) of children who initiated α2-adrenergic agonists and 78% (95% CI, 72.4%-83.4%) of children who initiated stimulants. Only daytime sleepiness was more common for those receiving α2-adrenergic agonists vs stimulants (38% vs 3%); several adverse effects were reported more commonly for those receiving stimulants vs α2-adrenergic agonists, including moodiness/irritability (50% vs 29%), appetite suppression (38% vs 7%), and difficulty sleeping (21% vs 11%).

Conclusions and relevance: In this retrospective review of health records of preschool-age children with ADHD treated in developmental-behavioral pediatric practices, improvement was noted in the majority of children who received α2-adrenergic agonists or stimulants, with differing adverse effect profiles between medication classes. Further research, including from randomized clinical trials, is needed to assess comparative effectiveness of α2-adrenergic agonists vs stimulants.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Harstad reported receiving compensation for serving as a medical reviewer for Understood.org, a website for parents of children with learning and attention issues, and grant funding from the Palmer Family Fund for Autism Research to conduct research related to autism spectrum disorder at Boston Children's Hospital. Dr Shults reported receiving grants from the Maternal Child Health Bureau/Health Resources and Services Administration, which is the grant that funds the Developmental Behavioral Pediatrics Research Network (DBPNet), the research network in which the work was conducted. Dr Barbaresi reported receiving grants from the Maternal Child Health Bureau/Health Resources and Services Administration, which is the grant that funds DBPNet, the research network in which the work was conducted. Dr Bax reported receiving grants from Health Resources and Services Administration funded as the Leadership Education in Neurodevelopmental and Related Disabilities program co-director outside the submitted work. Dr Blum reported receiving grants from the Federal Maternal Child Health Bureau Funding for DBPNet during the conduct of the study and royalties from Elsevier Publishing as editor of Nelson Textbook of Pediatrics and personal fees from the American Academy of Pediatrics and Temple University for speaking at continuing education courses and from the American Board of Pediatrics as the medical editor for the sub-board of developmental-behavioral pediatrics outside the submitted work. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Children Included in a Study of α2-Adrenergic Agonists vs Stimulants for Preschool-Age Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
Analyses were completed on first treatment interval, which consisted of all treatment episodes (defined as period of time during which child was prescribed a specific medication at a specific dose and specific frequency) for each medication. Mean dose is not reported for treatment episodes with less than 10 children. aOne child was excluded from an analysis that included adjusting for clustering by clinician because clinician data were missing.
Figure 2.
Figure 2.. Outcomes in a Study of α2-Adrenergic Agonists vs Stimulants for Preschool-Age Children With Attention-Deficit/Hyperactivity Disorder
The estimated relative risks and associated 95% CIs for reported medication improvement were obtained by first fitting logistic regression models and then using the approach suggested in Zhang and Yu to convert the estimated odds ratios and their associated 95% CIs to estimated relative risks. The logistic models accounted for clustering within clinicians by site using the approach suggested by LaVange et al that applies survey methods, with clinician treated as the primary sampling unit and site as the stratification variable. The adjusted models included age, autism spectrum disorder, and sleep disorder.

Comment in

References

    1. Danielson ML, Bitsko RH, Ghandour RM, Holbrook JR, Kogan MD, Blumberg SJ. Prevalence of parent-reported ADHD diagnosis and associated treatment among U.S. children and adolescents, 2016. J Clin Child Adolesc Psychol. 2018;47(2):199-212. doi:10.1080/15374416.2017.1417860 - DOI - PMC - PubMed
    1. Posner K, Melvin GA, Murray DW, et al. . Clinical presentation of attention-deficit/hyperactivity disorder in preschool children: the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). J Child Adolesc Psychopharmacol. 2007;17(5):547-562. doi:10.1089/cap.2007.0075 - DOI - PubMed
    1. Spira EG, Fischel JE. The impact of preschool inattention, hyperactivity, and impulsivity on social and academic development: a review. J Child Psychol Psychiatry. 2005;46(7):755-773. doi:10.1111/j.1469-7610.2005.01466.x - DOI - PubMed
    1. Wolraich ML, Hagan JF Jr, Allan C, et al. ; Subcommittee on Children and Adolescents With Attention-Deficit/Hyperactive Disorder . Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2019;144(4):e20192528. doi:10.1542/peds.2019-2528 - DOI - PMC - PubMed
    1. Barbaresi WJ, Campbell L, Diekroger EA, et al. . Society for Developmental and Behavioral Pediatrics clinical practice guideline for the assessment and treatment of children and adolescents with complex attention-deficit/hyperactivity disorder. J Dev Behav Pediatr. 2020;41(suppl 2):s35-s57. doi:10.1097/DBP.0000000000000770 - DOI - PubMed

MeSH terms